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AbstrAct
Objectives This study explored the divergence and 
convergence between funded research about type 1 
diabetes and the research agenda of people living with the 
condition and their carers.
Design, method, setting A secondary analysis was 
undertaken of existing data from two UK organisations 
who regularly work with patients and carers to identify 
research priorities. The research ideas of people with 
diabetes were identified in two ways: in 15 research 
question generation workshops involving approximately 
100 patients and carers, and in a James Lind Alliance Type 
1 Diabetes Priority Setting Partnership with approximately 
580 patients, carers and clinicians (clinician question 
submissions were excluded from analysis). A total of 
859 individual research questions were collected from 
patients and carers. Diabetes research funding activity 
was identified through extensive online searches which 
provided a total of 172 relevant research projects for 
analysis.
results The data were thematically analysed and 
areas of priority for research identified and compared 
between the patient and funded research agendas. The 
overall finding of this study is that there is substantial 
convergence between the two research agendas, 
alongside some important areas of divergence. The key 
areas of divergence were found in care delivery, injection 
issues, psychosocial impacts and women’s health. We also 
demonstrate how an apparently convergent priority can 
host significant differences in emphasis between patient-
generated and funded research agendas.
conclusions We offer a comparison of a funded research 
agenda with one that has been derived directly from 
people with type 1 diabetes without initial framing by 
researchers. This provided a rare opportunity to explore 
the viewpoints of the end-users of research and compare 
them to realised research as determined by researchers 
and research organisations.
bAckgrOunD
The incidence of type 1 diabetes (T1D) is 
rising globally.1 As a leading cause of heart 
disease, stroke and amputation the burden 
on people living with diabetes and health 
services is considerable.2 Well-targeted 
research has a key role to play in the devel-
opment of evidence-based treatments for the 
management and self-management of T1D. 
People living with diabetes are well placed to 
contribute to the development of this research 
in many ways, including suggesting areas for 
research they consider most important.
A key rationale for patient and public 
involvement (PPI) is that research carried 
out with members of the public should lead 
to research that is more relevant to people’s 
needs.3 Public involvement in the design 
and conduct of health research has devel-
oped significantly in recent years, and is now 
seen as a core component of good research 
practice. Major UK research funders such as 
the National Institute for Health Research 
(NIHR) and the Medical Research Council 
have patient and public representation on 
funding panels and require funding applica-
tions to demonstrate evidence of PPI.4
For PPI to be meaningful, patients and 
the public need to be able to exert influence 
throughout the research process, including 
the development of research agendas. 
Exploring issues of utility and acceptability to 
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Research
strengths and limitations of this study
 ► Empirical comparison of the research agendas of 
people with type 1 diabetes and funded research in 
this field.
 ► This is a rare opportunity to explore the research 
agendas of people with type 1 diabetes, in their own 
words, through thematic analysis.
 ► The analysed questions are the suggestions of the 
people who took part in James Lind Alliance Priority 
Setting Partnership activities or who took part in 
a PenCLAHRC (NIHR Collaboration for Leadership 
in Applied Health Research and Care South West 
Peninsula) workshop, therefore certain groups could 
be under-represented and other agendas within the 
diverse patient communities missed.
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patients before the agenda is set may increase uptake of 
research,5 generate research that is of interest to patients, 
allow outcomes meaningful to patients to be researched 
and reduce waste.6 7 INVOLVE, the NIHR’s advisory 
body for public involvement, defines PPI as “research 
carried out ‘with’ members of the public rather than ‘to’, 
‘about’ or ‘for’ them”.3 Applying this definition of PPI, 
there are few studies that report involving patients and 
carers in agenda setting for T1D research. An exception 
is the James Lind Alliance’s (JLA) top 10 research prior-
ities created in partnership with clinicians, patients and 
carers.8 Many diabetes agenda setting studies simply omit 
the patient perspective.9 10
Studies that do report patients’ diabetes research 
agendas often do not meet the INVOLVE definition of 
involvement above since the methods used to draw out 
these agendas effectively reduce patients to the level of 
research subjects; the research is ‘about’ them rather than 
conducted ‘with’ them. This is true for surveys, question-
naires and focus groups especially.11 12 These methods can 
be employed, as just one stage, within a wider collabora-
tive agenda setting process where involvement exists from 
beginning to end.13 14 On their own, however, they offer 
no opportunity for active involvement because the partic-
ipants are undertaking agenda setting tasks where there 
has been prior framing by the researchers. Ultimately, 
this may contribute to a supposed patient agenda that 
aligns with that of researchers when in reality a mismatch 
between the two exists. Further distortion can occur when 
prioritising research agendas as patient and carer ques-
tions may be at greater risk of rejection from the agenda 
setting process.15
It is important then to compare research agendas to 
ensure that patients’ concerns are reflected in ongoing 
research. Studies comparing the health research agendas 
of the public with those of researchers are very rare.16 17 
A literature search carried out in relation to this study 
only located two such comparisons of diabetes research 
agendas by one author.12 18 The first study compared 
patient and researcher preferences and found a 
mismatch, and the second compared the proportions of 
research topics and also found that the distribution of 
funded research did not reflect patient concerns. There is 
no ‘gold standard’ currently for producing a ‘researcher’ 
derived agenda for comparative purposes. Existing 
methods include searching for relevant published and 
unpublished literature,16 compiling data from ongoing 
clinical trials17 and using published abstracts from a rele-
vant conference.18
The aim of this study was to explore the divergence 
and convergence between the agenda demonstrated in 
T1D research and the research agenda of people with 
T1D and carers elicited using participatory approaches 
aligned with the principles of public involvement.19 20 
This provides a rare opportunity for an exploration of an 
agenda directly expressed by patients and carers in their 
own words.
setting
This study uses existing data from two UK organisations 
who regularly work with patients and carers to identify 
research priorities. The first organisation is the NIHR 
Collaboration for Leadership in Applied Health Research 
and Care South West Peninsula (PenCLAHRC).21 
PenCLAHRC involves patients and carers in both the 
identification and prioritisation of research questions 
that address patient and clinical concerns.22 Methods 
include question generation workshops which enable 
the public to develop research uncertainties in their 
own words. Fifteen research question generation work-
shops were carried out by the PenCLAHRC PPI team 
between January 2010 and December 2011. These work-
shops involved approximately 100 patients and carers, 
including 22 people who identified themselves as either 
a carer of or person with T1D. Recruitment for the work-
shops was achieved by sending adverts to local organisa-
tions (eg Healthwatch and the Diabetes Association local 
branch). Workshop attendees were typically retired and 
white, reflecting the local South West demographic.
The largest proportion of patient questions was 
provided by the second organisation, the JLA, which is 
a non-profit making initiative founded in 2004. It brings 
patients, carers and healthcare professionals together 
in Priority Setting Partnerships to identify and prioritise 
the unanswered questions about treatments that they 
agree are most important.14 Priority Setting Partner-
ships work to identify and prioritise the uncertainties, or 
unanswered questions, about treatments which patients, 
carers and clinicians want research to address. In the 
first stage of these partnerships, patient, carer and clini-
cian uncertainties are gathered through a survey where 
respondents can write their questions in free text, without 
prior framing by researchers.23 During the same time 
period as the PenCLAHRC workshops, research ideas 
were submitted by people with diabetes to the JLA Type 
1 Diabetes Priority Setting Partnership, which was funded 
by the Insulin Dependent Diabetes Trust. Research ideas 
were submitted to the Partnership through an online 
and paper survey, which was widely advertised by various 
diabetes charities, the Diabetes Research Network, the JLA 
and NHS Evidence—diabetes. The JLA Type 1 diabetes 
partnership method for priority setting is described in 
detail elsewhere.8
MethODs
Data collection: patients and carers’ research questions
Both organisations provided ‘raw’ data in the form of indi-
vidual questions, as expressed by the workshop and survey 
respondents. The data used in this study were received in 
their original state, prior to any ‘cleaning’ that the organ-
isations may have done. It is important to note two key 
points about the data. First, that while the JLA Partner-
ship itself removed questions not related to treatments 
due to the focus of the JLA method, our study examined 
all suggestions submitted by people with T1D and carers 
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Table 1 Sources searched for diabetes research projects 
funded between January 2010 and January 2012
Number Organisation
Codable type 1 
diabetes projects
1 The Novo Nordisk UK 
Research Foundation
6
2 Novo Nordisk 5
3 Diabetes UK 38
4 Diabetes Research & Wellness 
Foundation UK
9
5 Biotechnology and Biological 
Sciences Research Council 
(BBSRC)
1
6 British Heart Foundation 11
7 Chief Scientist Office 5
8 NIHR 28
9 Wellcome Trust 11
10 Medical Research Council 1
11 WHO trials register 11
12 ClinicalTrials.gov 46
13 Picker Institute 0
14 Royal College of Nursing 
Foundation
0
15 Local diabetes research 
network contact
0
16 Leverhulme 0
17 Health Foundation 0
18 ESRC 0
in their unedited form, prior to any cleaning or rejection 
(see Snow et al for an analysis of the rejected questions15). 
Second, because the analysed data are unedited and 
directly from the public, some of the questions raised may 
already be addressed by an existing evidence base. These 
questions have not been removed, as they were in the JLA 
process, because they reflect patient concerns.
A total of 877 individual uncertainties were collected 
from patients and carers. After removing items that were 
not related to T1D (eg, about type 2 diabetes or an unre-
lated topic), 859 individual patient questions were avail-
able for analysis.
Data collection: funded research studies
To establish a comparative, researcher-derived data set, 
we searched for information about research that had 
been funded within the same time period as the ‘patient’ 
agenda setting exercises (January 2010 to December 
2011). We defined ‘funded research’ as UK-based research 
that was ongoing, for example, a clinical trial in the 
recruitment phase or research that had been approved 
for funding by a provider but was not yet under way. By 
limiting our inclusion criteria to recently funded or newly 
underway studies we hoped to derive an agenda that was 
as chronologically close as possible to the patient agenda 
while still using publicly available existing data. Searches 
were conducted on 18 websites and databases, identified 
by an information specialist, to obtain data about diabetes 
research funded between January 2010 and December 
2011 in the UK (see table 1 for details).
The title and abstract of the research records were 
downloaded providing a total of 231 funded research 
projects. The projects were screened by KB to ensure 
that they were about T1D and that the project was solely 
based in the UK. After duplicates (individual project 
found repeated through various sources), non-T1D 
projects (eg, type 2 diabetes) and non-UK projects were 
removed, 172 unique T1D research projects were avail-
able for coding.
Of the 18 sources initially searched, 12 contained infor-
mation related to T1D research (table 1). To reduce the 
likelihood of a bias in the research projects analysed, in 
terms of type of research, extensive attempts were made 
to cover a full range of research funders including social 
research funders, rather than simply biomedical research 
funders (which were easier to locate due to trial registers, 
and so on). None of the social research funders searched 
resulted in T1D research projects within the time period 
of interest although they had previous links with diabetes 
research which was why they were included in the search 
process. The breakdown of the number of research proj-
ects that were analysed by funder type is shown in table 2.
ethics statement
We consider our study to be exempt from requiring 
ethical approval. The original public involvement agenda 
setting activities conducted by the JLA and PenCLAHRC, 
described above, were exempt from requiring ethical 
approval under guidance published by the NHS National 
Patient Safety Agency National Research Ethics Service 
and INVOLVE.24 The data from those activities are 
publicly available.25 This is a secondary analysis of those 
existing data.
Data analysis
Both data sets were individually thematically analysed in 
order to identify inductively emergent research themes.26 
In the early development of this project we opted to 
employ a form of thematic analysis, over other forms of 
analysis such as content analysis, because we were inter-
ested in understanding the nature of the questions. For 
each data set, the initial stage of analysis involved familiar-
isation with the data by KB, resulting in the initial develop-
ment of a list of recurrent codes. KC also independently 
undertook an initial analysis of a subset (10%) of both 
data sets. Specialist knowledge was provided by a consul-
tant endocrinologist who assisted in identifying codes for 
the funded research data. NVivo, a qualitative software 
indexing program, was used to facilitate data organisation, 
coding and retrieval. To develop the codes, each question 
and research study was considered in terms of its key focus. 
For example, the question ‘Can homeopathic medicines 
provide beneficial use in diabetic care?’ was coded to the 
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Table 2 Summary of number of research projects by 
funder type
Funder type Source
Total 
projects
Mixed 1. ClinicalTrials.gov
2. WHO—mixed funder 
register
57
Diabetes Charity 1. Diabetes Research & 
Wellness Foundation UK
2. Diabetes UK
47
UK Government 1. BBSRC
2. Chief Scientist Office
3. MRC
4. NIHR
35
Charity (other) 1. British Heart Foundation
2. The Novo Nordisk UK 
Research Foundation
3. Wellcome
28
Industry 1. Novo Nordisk (industry) 5
Funder type categories:
Mixed: These sources contained multiple types of research funder 
including charity (diabetes and other), UK government funding and 
industry.
Diabetes Charity: These sources only funded research related to 
diabetes. Funds are raised through charitable means.
Charity (other): These sources funded research into different 
conditions and types of biomedical research, including T1D.
Funds are raised through charitable means.
UK Government: These sources funded research into different 
conditions and types of biomedical research, including T1D. Funds 
are provided by grants via government research organisations.
Industry: These sources funded research into different conditions 
and types of biomedical research, including T1D.
Funds are provided by business and pharmaceutical companies.
category ‘Alternative therapies’. KC and KB then met to 
consult on the codes generated and to discuss, refine and 
agree to a set of codes for each data set. KB completed 
the coding of both data sets, in frequent consultation with 
KC as well as a third researcher (AG). KC and KB met to 
reach a consensus on the key themes from both data sets. 
Finally, both data sets were interpreted as a whole, identi-
fying areas of divergence and convergence.
results
The results showed that there is convergence between the 
two research agendas; there are also some notable areas 
of divergence. We will explore areas of divergence in 
greater depth than the convergent themes in an attempt 
to understand what is missing from the agenda from a 
patient’s point of view.
Areas of convergence
‘Control and complications’ was an important theme 
for both the funded research agenda and the patient 
research agenda. This broad theme relates to all aspects 
of blood sugar control and complications associated 
with T1D. Monitoring blood sugar levels was a key area 
of uncertainty; both agendas were interested in finding 
better methods of monitoring blood glucose both in 
terms of providing greater accuracy and in providing 
more acceptable and less invasive methods. Uncertainties 
about managing control in particular circumstances, such 
as exercise, were identified in both data sets. There was 
also a range of queries about the relationship between 
maintaining good control and the risk of developing 
complications:
“Long term effects of maintaining good blood glucose 
control and its impact on ‘diabetic’ complications.” 
(People with diabetes research question)
‘The objective…is to test whether metformin tablets 
added in with insulin treatment in type 1 diabetes 
can prevent the early blood vessel complications 
which lead to heart attacks and strokes.’ (Objective of 
funded study, WHO)
Another notable area of convergence between the 
two agendas was themed by the authors as ‘causes and 
cures’ for people with diabetes and ‘cell research’ within 
funded research. Within the patient research agenda 
broad questions were posed about finding the causes and 
cure for T1D: ‘How can we cure type 1 diabetes?’ ‘What are 
the causes?’ This may not immediately appear to fit with 
a funded research title such as ‘Development of regulatory 
B cell assay in type 1 diabetes’ (Title of funded research, 
Diabetes Research and Wellness Foundation). However, 
the abstract of this research protocol reveals that there is 
indeed a shared agenda focused on exploring the causes 
of diabetes: ‘This research will be important for understanding 
why people develop T1DM.’
While there are clear differences between the ways in 
which the funded research questions and people with 
diabetes express the notion of control and complications, 
and causes and cures, the data suggested that funded 
studies are addressing priority areas for the end-users of 
those studies.
Areas of divergence
Notable divergent themes were: care delivery, injection 
issues, psychosocial impacts and women’s health.
Care delivery
The theme of ‘care delivery’ featured in both agendas, but 
there was little agreement on the topics to be researched. 
For people with diabetes there were two aspects of care 
delivery in need of further research: access to equipment 
and variation in care. While the first was concerned with 
the day-to-day mechanisms of managing T1D, both topics 
were informed by the unequal treatment that people 
with diabetes can experience, depending on location and 
local policies. People felt that better provision of essential 
items, such as blood test strips, would be cost saving in the 
long term by preventing complications:
‘Can we have some conclusive evidence to prove to 
the nhs that in the long run it is much cheaper to 
give us more blood test strips than to treat us for the 
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severe complications that arise when we have poor 
control through insufficient testing?’ (People with 
diabetes research question)
Variation in care is about the disparity in treatment 
people with diabetes can face across the country and 
questions were raised about this unequal delivery of care:
‘Why are quality structured education programmes 
not delivered in all diabetes centres in the UK?’ 
(People with diabetes research question)
The care delivery agenda of the funded research 
programmes was much broader and no distinct subthemes 
such as access and variation emerged. There was some 
overlap with patient concerns. For example, one study 
aimed to understand the geographical variations in the 
rates of amputation and foot ulceration in patients with 
diabetes: ‘Social and geographical impact on diabetes related- 
foot ulcers and amputations’ (Title of funded study, Chief 
Scientist Office). However, the funded research within 
the theme of care delivery showed a different emphasis 
to that of the patient agenda, focusing on areas such as 
non-adherence and uptake of screening:
‘Understanding factors leading to low uptake of 
diabetic retinopathy screening in Primary Care.’ 
(Title of funded study, NIHR)
‘Identifying medication nonadherence: using Scottish 
routine healthcare data to support improvements in 
patients care.’ (Title of funded study, Chief Scientist 
Office)
So while ‘Care delivery’ was prioritised in both funded 
research and patient questions, there was a clear differ-
ence in focus. From the perspective of people with 
diabetes, lack of service provision is a major concern. 
From the perspective of researchers, an important 
concern is services not being used. This demonstrates 
how an apparently shared priority may host significant 
differences in emphasis between patient-generated and 
funded research agendas.
Injection issues
This theme was clearly important to people with diabetes 
while notably absent in the funded research. Questions 
in this theme reflected patient concerns about the need 
for alternative methods of insulin delivery other than 
injections. Patients expressed hopes that oral, inhalation 
or skin patch methods could be developed and prove 
effective:
‘Could insulin be given in tablets instead of having 
to be injected?’ (People with diabetes research 
question)
‘…are there further possibilities that inhalation or 
any other methods of insulin delivery would work in 
the future for type 1 diabetes?’ (People with diabetes 
research question)
It is not possible to ascertain from the data whether the 
question submitters were aware of the existing evidence 
base and the difficulties in these research fields (eg, 
limited absorption and enzyme degradation),27 and 
are calling for renewed development in these areas or 
whether they are asking for a novel approach. Be that as 
it may, our data show that patients want alternatives to 
be ‘quicker and pain free’, ‘make life easier’ and be a better 
method of delivery than the ‘very painful and inconvenient’ 
injections. The extent of these questions and the recur-
ring topic of pain provide insight into outcomes that are 
important to people with diabetes.
Psychosocial impacts
The theme of ‘psychosocial impacts’ of diabetes covered 
a range of concerns such as peer support, psychological 
well-being and its effects on diabetes management, and 
the mental health effects of living with diabetes. This topic 
was of importance for people with diabetes yet was absent 
from the funded research agenda. People with diabetes 
were interested in the way in which psychosocial aspects 
affect their management and control of blood glucose:
‘Does regular contact with others with type 1 diabetes 
help with blood glucose control and/or mental well-
being?’ (People with diabetes research question)
They also wanted to know about the way in which living 
with diabetes affects their psychosocial well-being: ‘psycho-
logical impact of something that imposes so much on your day 
to day life’. Following on from establishing the psychoso-
cial impacts, questions were raised about how to support 
people: ‘What is the most effective support psychologically for 
people with Type 1 diabetes?’
In this theme, people with diabetes seemed to be aware 
of the divergence between their interests and current 
research. The questions pointed out that this was an area 
felt by patients to be under-researched and that other 
topics were given prominence. This was not apparent in 
other themes:
‘The psychological and emotional effect of living 
with diabetes is chronic and does not seem to be 
addressed.’ (People with diabetes research question)
‘From what I have seen research seems to centre 
around insulin and equipment—I would like to see 
research around coping mechanisms and how the 
most successful at dealing with the condition do it.’ 
(People with diabetes research question)
Women’s health
This theme covered a range of gender-specific issues, 
such as pregnancy, menstruation and menopause. A 
subtheme, menstruation and menopause, was completely 
absent from the funded research agenda. Patients were 
concerned with the effects of menstruation and meno-
pause on diabetes management. Uncertainties centred 
on how hormone changes brought about by menstruation 
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and menopause affected diabetes, adding in a layer of 
additional complications for women:
‘Hormones have a major effect on diabetes in women. 
This continues with childbirth and menopause. The 
full impact of hormones needs to be addressed.’ 
(People with diabetes research question)
‘What is the effect of the menstrual cycle on Diabetes 
management?’ (People with diabetes research 
question)
While menstruation and menopause were not 
addressed by funded research, a second subtheme within 
‘Women’s health’, perinatal questions were found in 
the research set. Research questions addressed in this 
subtheme covered diabetes management in pregnancy 
and the effects of maternal diabetes on babies:
‘The effects of changes in maternal blood glucose 
concentration on placental blood flow and fetal 
cardiovascular function during pregnancy in women 
with Type 1 diabetes.’ (Title of funded study, Diabetes 
UK)
‘What are the effects of being pregnant on your 
diabetes and the unborn baby?’ (People with diabetes 
research question)
This divergence around menstruation and meno-
pause, affecting all women with T1D, suggests to us that 
researchers not only need to talk to patients about their 
interests and concerns. They also need to ensure they are 
reaching diverse groups within those patient communities
liMitAtiOns
This study is based on a relatively large sample of patient 
and carer questions which have not been modified by 
researchers, clinicians or policymakers. However, these 
questions are the suggestions of the people who took part 
in JLA Priority Setting Partnership activities or who took 
part in a PenCLAHRC workshop. It might be that certain 
groups are under-represented and that other agendas 
within the diverse patient communities have been missed. 
The study was undertaken at a particular point in time and 
may not reflect research agendas at other times. While 
we took steps to ensure the two data sets were as chrono-
logically close as possible, grant applications to funding 
bodies take time to develop before they ultimately receive 
funding, meaning that some time lag between the two 
agendas is inevitable. Finally, none of the research team 
had live experience of T1D.
cOnclusiOn
Using two robust direct methods of public engagement, 
this study found an encouraging level of agreement 
between the research agenda of people with T1D and 
that of recent funded research. Despite this conver-
gence, important concerns for people with T1D were 
conspicuously absent from the funded research. Absent 
topics included questions about the effects of menopause 
and menstruation on diabetes management and ques-
tions about how the pain and impact of injecting could be 
removed. Also absent were questions about the psychoso-
cial impacts of living with diabetes. Questions within this 
topic were the only ones that pointed to an awareness of a 
divergence from the funded research agenda.
The theme of ‘care delivery’ was present in both 
research agendas. The funded research was concerned 
with adherence and screening while the public research 
agenda focused on the inequalities and variation in care. 
Our exploration of these research agendas suggests that 
involvement is needed to ensure that patient concerns 
are fully reflected within an agenda, avoiding superficial 
agreement which masks differences of perspective within 
a topic.
Where people with diabetes have expressed uncer-
tainties that already have an existing evidence base, this 
suggests that research findings are not reaching the 
patient community requiring better communication of 
research and better dissemination to a wider range of 
audiences. However, if a topic is repeatedly put forward 
as a priority despite an existing evidence base (eg, oral 
insulin) consideration needs to be given as to whether 
those services or treatments are adequately addressing 
patient needs.
Our findings suggest that funded diabetes research 
may be neglecting questions about the everyday reality of 
living with T1D, about quality of life including pain and 
about the particular needs of women at different stages 
of the life cycle. They suggest that the diabetes research 
community could increase the relevance of its work for 
patients by working with patients very early in the research 
development phase.
It is encouraging for the T1D community that our study 
found considerable agreement between the two agendas. 
However, the recent paper by Crowe et al17 demonstrates a 
continued divergence in health research agendas gener-
ally. Our work suggests that there may be significant vari-
ation between specific conditions and within condition 
topics. The data generated by these exercises create great 
potential for marrying up the two agendas and enhancing 
both communication of convergence and action to 
address divergence.
The findings of this research contribute to the limited 
evidence base around public involvement and research 
agenda setting. We demonstrate the need for considered, 
meaningful and direct involvement of patients in agenda 
setting that includes diverse groups within specific patient 
communities to ensure that the full range of issues expe-
rienced by people living with healthcare conditions can 
be addressed.
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